Acamprosate in the treatment of alcohol dependence
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support. Acamprosate is a synthetic taurine analogue that seems to act centrally to restore the normal activity of glutamatergic neurotransmission altered by chronic alcohol exposure. Over the past 15 years, the safety and efficacy of acamprosate for alcohol dependence have been well established in multiple double-blind, placebo-controlled trials. Overall, acamprosate has been consistently associated with greater beneficial effects on measures of alcohol abstinence compared with placebo. Specifically, patients treated with acamprosate achieve greater rates of complete abstinence, longer times to first drink and/or increased duration of cumulative abstinence when compared with placebo. Acamprosate received approval by the US FDA for the treatment of alcohol dependence in July 2004 and is currently prescribed in 28 countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444 · cited 3×
“Unfortunately, psychosocial support without complementary pharmacological treatments has had only limited success in achieving prolonged abstinence [6], with 50% of alcoholics suffering a relapse within 3 months of detoxification and ≤ 70% relapsing within 1 year [6,9,14-17].”
BackgroundMethodDrug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255 · cited 5×
“Upon removal of alcohol, this excitatory state remains unopposed, resulting in hyperactivity and dysfunction that is characteristic of alcohol withdrawal [9].”
BackgroundInfluentialStreeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228 · cited 1×
“Two meta-analyses reported the effect of naltrexone to be small-tomoderate [25,26], whereas a larger multi-centre clinical trial involving 627 patients found no significant difference in the number of days to relapse between placebo and naltrexone [27].”
ResultNeuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201
Heyser, C. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00130-9 · Cited by 176
The COMBINE Study Research Group (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2003.tb02873.x · Cited by 174
Dahchour, A., De Witte, P., Bolo, N., Nédélec, J.-F., Muzet, M., Durbin, P., & Macher, J.-P. (1998) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(98)00016-x · Cited by 165
The efficacy of disulfiram: a review of outcome studies
HUGHES, J. C., & COOK, C. C. H. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb03370.x · Cited by 162 · cited 1×
“Placebo-controlled studies with disulfiram have been inconclusive in aggregate [9,18] although outcomes of patients who take disulfiram are improved when the drug is taken under direct supervision [19].”
Background
Cited by
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Self-citationO'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 484
Exposure to the Taste of Alcohol Elicits Activation of the Mesocorticolimbic Neurocircuitry
Filbey, F. M., Claus, E., Audette, A. R., Niculescu, M., Banich, M. T., Tanabe, J., Du, Y. P., & Hutchison, K. E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301513 · Cited by 270
Schmidt, H. D., & Pierce, R. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05144.x · Cited by 254
Metadata
- Authors
- Mason, B. J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2005-10
- Volume
- 6
- Issue
- 12
- Pages
- 2103-2115
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2117060002
- Cited by
- 46
- References
- 13
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acamprosate in the treatment of alcohol dependence. https://app.cochat.ai/papers/10.1517/14656566.6.12.2103
- The paper
- Mason, B. J. (2005). Acamprosate in the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.6.12.2103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.